2025-06-17-花旗集团-科莱恩公司（CLN）_科莱恩公司（CLN.S）_首席财务官路演反馈——信心十足的信息_11页_309kb

Clariant AG (CLN.S) Summary

Core Content Overview

Clariant AG (CLN.S) is the subject of a Citi Research report that highlights its financial performance, strategic initiatives, and market outlook as of June 17, 2025. The report outlines key takeaways from investor meetings with the CFO, including resilient demand in the second quarter of 2025, ongoing restructuring efforts, M&A strategy, and challenges from trade uncertainty and regulatory issues.

Key Takeaways from CFO Roadshow

• Demand Resilience in 2Q25: Demand has shown resilience in the second quarter of 2025, with group asset utilization expected to rise quarter-over-quarter. Management is confident in achieving a margin target of 17-18% for the year and potentially higher in 2025.

• Sales Growth Uncertainty: While management expects to meet the 3-5% sales growth target for FY25, confidence in achieving this is lower due to the uncertainty surrounding tariffs and trade tensions affecting demand in the second half of the year.

• Restructuring Progress: The restructuring program has largely been completed, and restructuring charges are expected to fall below 0.5% of sales. This is expected to improve free cash flow conversion over time.

• M&A Strategy: Management is actively looking for consumer-focused bolt-on acquisitions, with a preference to see leverage fall below 2x before pursuing further deals. The potential sale of the Industrial Park Fechenheim could aid in this effort.

• Ethylene Price Fixing and PFAS Liabilities: Management acknowledges the ethylene price fixing claims and the PFAS liabilities, which have created uncertainty for investors. The statute of limitations for these claims closes in 2027, and management remains focused on delivering consistent margin and cash flow improvements.

Valuation and Investment Outlook

• Target Price: Citi Research sets its target price at SFr14, based on a DCF valuation using a WACC of 9%, a long-term growth rate of 2%, and an ROCE of 9%.

• Expected Returns: The expected share price return is 67.5%, and the expected dividend yield is 5.1%, leading to a total return of 72.6%.

• Free Cash Flow (FCF): FCF is expected to improve as restructuring charges decline, with a current conversion rate of 40%. Management sees potential to lift this above the current target in the long term, though a SAP HANA system upgrade is expected to be a pending cash use in the next 3-5 years.

Risks

• Persistent Weak Demand: Continued weak demand in certain segments may negatively impact asset utilization and profitability.

• Lucas Meyer Integration: Integration challenges due to cultural and regional differences could affect synergy realization, especially if key personnel leave.

• Catalysis Segment: Sales in the Catalysis segment are expected to remain weak in 2025, with recovery anticipated in 2026. There is a risk that plant operators may delay catalyst refills if chemical utilization remains low.

• FX Exposure: Clariant's global operations expose it to foreign exchange (FX) risks, which could impact financial performance.

• Trade Uncertainty: Tariffs and trade wars may reduce volume or increase costs, negatively affecting earnings.

Investment Ratings and Catalyst Watch

• Investment Ratings: Citi Research uses Buy, Neutral, and Sell ratings, based on expected total return (ETR) and risk. A Buy rating is assigned for ETR of 15% or more for non-high-risk stocks, and 25% or more for high-risk stocks.

• Catalyst Watch: Citi Research may also issue Catalyst Watch or Short-Term Views (STV) to indicate near-term price movements in response to specific events. These are separate from the fundamental equity rating and reflect short-term expectations.

• Recent Ratings and Target Price Changes:

  • 08-Jul-24: Added STV with an upside call.
  • 08-Aug-24: Removed STV.
  • 12-Nov-24: Added STV again with an upside call, then removed it.

Analyst Information and Affiliations

• Analysts: The report was prepared by Ranulf Orr, CFA, Sebastian Satz, CFA, and Omi Pallavi.

• Affiliations: The analysts are employed by Citigroup Global Markets Limited. Non-US research analysts are not registered with FINRA and may not be subject to the same communication restrictions.

Important Disclosures

• Conflict of Interest: Citi Research and its affiliates may have a conflict of interest due to business relationships with Clariant. The Firm has mechanisms in place to manage such conflicts.

• Liquidity and Trading: The Firm may act as a liquidity provider or principal in transactions involving the recommended financial instruments. It may also issue or trade in securities related to the subject company.

• Regulatory Compliance: The report includes compliance disclosures, including those related to FINRA, Israeli, European, and Turkish regulations. These disclosures emphasize the non-binding nature of the report and the importance of individual investor due diligence.

• Past Performance and Forecasts: Past performance is not indicative of future results. Forecasts and projections are based on current information and may change.

Summary Table

Key Area	Summary
Demand and Performance	Resilient in 2Q25; margin target of 17-18% expected, but sales growth is uncertain due to trade issues.
Restructuring	Completed largely, with restructuring charges falling below 0.5% of sales.
M&A Strategy	Focus on consumer-oriented bolt-ons; leverage target below 2x.
Ethylene and PFAS Issues	Management acknowledges these challenges but remains focused on margin and cash flow improvements.
Valuation	Target price at SFr14; based on DCF with WACC of 9%, growth rate of 2%, and ROCE of 9%.
Risks	Weak demand, integration challenges, FX exposure, and trade uncertainty.
Investment Ratings	Buy, Neutral, and Sell based on ETR and risk; Catalyst Watch and STV for short-term movements.
Disclosures	Includes conflict of interest, liquidity, and regulatory compliance notes.